Art. -Nr.: HY-N2187

Deoxyshikonin

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.83%
CAS. Nr.: 43043-74-9
Formel: C₁₆H₁₆O₄
Molecular Weight:272.30

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Deoxyshikonin Chemical Structure

CAS. Nr.: 43043-74-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]^[3]

HIF-1α

HIF-1β

PI3K

Alle HIF/HIF Prolyl-Hydroxylase Isoform-spezifische Produkte anzeigen :

Alle PI3K Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	6.83 μM Compound: SK-3	Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay	[PMID: 39129245]
AU565	IC₅₀	0.92 μM Compound: 1	Cytotoxicity against human AU565 cells after 48 hrs by MTT assay Cytotoxicity against human AU565 cells after 48 hrs by MTT assay	[PMID: 20405844]
DU-145	IC₅₀	1.24 μM Compound: 1	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 20405844]
HCT-116	IC₅₀	15.46 μM Compound: SK-3	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay	[PMID: 39129245]
HeLa	IC₅₀	0.85 μM Compound: 1	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20405844]
Hep 3B2	IC₅₀	6.02 μM Compound: 1	Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay	[PMID: 20405844]
HepG2	IC₅₀	0.9 μM Compound: 1	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 20405844]
HepG2	IC₅₀	10.5 μM Compound: SK-3	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay	[PMID: 39129245]
HT-29	IC₅₀	5.12 μM Compound: 1	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20405844]
LNCaP	IC₅₀	12.21 μM Compound: 1	Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay	[PMID: 20405844]
MCF7	IC₅₀	0.79 μM Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20405844]
MDA-MB-231	IC₅₀	5.08 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20405844]
NIH3T3	IC₅₀	5.84 μM Compound: 1	Cytotoxicity against mouse 3T3 cells after 48 hrs by MTT assay Cytotoxicity against mouse 3T3 cells after 48 hrs by MTT assay	[PMID: 20405844]
PC-3	IC₅₀	4.29 μM Compound: 1	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 20405844]
SAOS-2	IC₅₀	0.85 μM Compound: 1	Cytotoxicity against human Saos2 cells after 48 hrs by MTT assay Cytotoxicity against human Saos2 cells after 48 hrs by MTT assay	[PMID: 20405844]
SK-BR-3	IC₅₀	0.69 μM Compound: 1	Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay Cytotoxicity against human SKBR3 cells after 48 hrs by MTT assay	[PMID: 20405844]
Vero	IC₅₀	0.66 μM Compound: 1	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 20405844]

In Vitro

Deoxyshikonin (6.25-100 μg/mL; 48 h) inhibits the growth of human colonic cancer cells^[1].
Deoxyshikonin (25-100 μg/mL; 24, 48 h) induces early apoptotic cells death^[1].
Deoxyshikonin (25-100 μg/mL; 48 h) leads to a dose-dependent increase in the percentage of cells at G0/G1 phase^[1].
Deoxyshikonin (25-100 μg/mL; 48 h) exerts a decrease of PI3K, p-PI3K, Akt, p-Akt308 and mTOR proteins expression in HT29 and DLD-1 cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

Caco-2, HCT116, DLD-1 and HT29 cells
Concentration:

6.25, 12.5, 25, 50 and 100 μg/mL
Incubation Time:

48 h
Result:

At low concentration inhibited the growth of human colonic cancer cells including DLD-1, HCT-116, Caco-2 and HT29 cells.
Had IC₅₀ values of 31.00 μM at 24 h, while 10.97 μM at 48 h in HT29 cells.

Apoptosis Analysis^[3]

Cell Line:

HT29 cells
Concentration:

25, 50 and 100 μg/mL
Incubation Time:

24 or 48 h
Result:

The ratio of early apoptotic cells increased from 1% to 29% in a dose-dependent manner by being treated with 0-50 μg/mL at 48 h.

Cell Cycle Analysis^[3]

Cell Line:

HT29 cells
Concentration:

25, 50 and 100 μg/mL
Incubation Time:

48 h
Result:

The percentage of G0/G1 cells increased from approximately 44% to 67% in HT29 cells after treatment with 0-50 μg/mL, accompanied by a significant decrease in the percentage of cells at S and G2/M phases.

Western Blot Analysis^[3]

Cell Line:

HT29 and DLD-1 cell lines
Concentration:

25, 50 and 100 μg/mL
Incubation Time:

48 h
Result:

Exerted a decrease of PI3K, p-PI3K, Akt, p-Akt308 and mTOR proteins expression in HT29 and DLD-1 cell lines.

In Vivo

Deoxyshikonin (20 mg/kg; intraperitoneal injection; every two days for 13 days) markedly suppresses the growth of xenograft tumours on day 5, 9 and 11 with 20 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male BALB/c nude mice of 10-14 g with DLD-1 cells^[1]
Dosage:

20 mg/kg
Administration:

Intraperitoneal injection; every two days for a total of 13 days
Result:

Markedly suppressed the growth of xenograft tumours on day 5, 9 and 11 with 20 mg/kg, while there were no significant changes in body weight of the mice.

Chemical Information

CAS. Nr. 43043-74-9
Appearance Solid
Molecular Weight 272.30
Formel C₁₆H₁₆O₄
Color Brown to reddish brown
SMILES

O=C1C(CC/C=C(C)/C)=CC(C2=C1C(O)=CC=C2O)=O
Structure Classification
- Quinones
- Naphthalene Quinones
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (3)

All Cell Proliferation/Viability AssayCell Imaging/StainingIFFlow CytometryIP

Sort by:

Journal Impact Factor

Nat Commun

Physiological premature aging of ovarian blood vessels leads to decline in fertility in middle-aged mice. [Abstract]

2025 Jan 2;16(1):72. PMID: 39747922
J Exp Clin Cancer Res

Disruption of HSPA8-GEMIN5 interaction suppresses colorectal cancer by impaired splicing-translation coupling-mediated proteostasis imbalance. [Abstract]

2026 Jan 16;45(1):47. PMID: 41545989

Deoxyshikonin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2026 Jan 16;45(1):47. [Abstract]

Dose-dependent inhibition of cell viability in human CRC SW480 and DLD-1 cells, measured using a CCK-8 assay treated with Deoxyshikonin (DSHK).

Deoxyshikonin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2026 Jan 16;45(1):47. [Abstract]

Colony formation assay for the analysis of the Deoxyshikonin (DSHK) (1, 2, 4 μM)-mediated suppression of cell proliferation in SW480 and DLD-1 cells.

Deoxyshikonin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2026 Jan 16;45(1):47. [Abstract]

EdU fluorescence staining to detect the DNA replication activity after 24 h of Deoxyshikonin (DSHK) (1, 2, 4 μM) exposure.

Deoxyshikonin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2026 Jan 16;45(1):47. [Abstract]

Annexin V-FITC/PI dual-staining flow cytometry to quantify the Deoxyshikonin (DSHK) (1, 2, 4 μM)-induced apoptosis after 24 h of treatment.

Deoxyshikonin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2026 Jan 16;45(1):47. [Abstract]

Endogenous Co-IP analysis of the HSPA8-GEMIN5 interaction intensity in SW480 and DLD-1 cells after treatment with gradient concentrations of Deoxyshikonin (DSHK) (1, 2, 4 μM) (24 h).
Microb Pathog

Deoxyshikonin inhibited rotavirus replication by regulating autophagy and oxidative stress through Sirt1/FoxO1/Rab7 axis. [Abstract]

2023 May:178:106065. PMID: 36907361

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 33.33 mg/mL (122.40 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6724 mL

18.3621 mL

36.7242 mL

5 mM

0.7345 mL

3.6724 mL

7.3448 mL

10 mM

0.3672 mL

1.8362 mL

3.6724 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Prangsaengtong O, et al. Enhancement of Lymphangiogenesis In Vitro via the Regulations of HIF-1α Expression and Nuclear Translocation by Deoxyshikonin. Evid Based Complement Alternat Med. 2013;2013:148297. [Content Brief]

[2]. Zhang S, et al. Antibacterial effects of Traditional Chinese Medicine monomers against Streptococcus pneumoniae via inhibiting pneumococcal histidine kinase (VicK). Front Microbiol. 2015 May 20;6:479. [Content Brief]

[3]. Yuzhen Zhu, et al. Deoxyshikonin isolated from Arnebia euchromainhibits colorectal cancer by down-regulating the PI3K/Akt/mTOR pathway. Pharm Biol. 2019 Dec;57(1):412-423. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6724 mL	18.3621 mL	36.7242 mL	91.8105 mL
	5 mM	0.7345 mL	3.6724 mL	7.3448 mL	18.3621 mL
	10 mM	0.3672 mL	1.8362 mL	3.6724 mL	9.1811 mL
	15 mM	0.2448 mL	1.2241 mL	2.4483 mL	6.1207 mL
	20 mM	0.1836 mL	0.9181 mL	1.8362 mL	4.5905 mL
	25 mM	0.1469 mL	0.7345 mL	1.4690 mL	3.6724 mL
	30 mM	0.1224 mL	0.6121 mL	1.2241 mL	3.0604 mL
	40 mM	0.0918 mL	0.4591 mL	0.9181 mL	2.2953 mL
	50 mM	0.0734 mL	0.3672 mL	0.7345 mL	1.8362 mL
	60 mM	0.0612 mL	0.3060 mL	0.6121 mL	1.5302 mL
	80 mM	0.0459 mL	0.2295 mL	0.4591 mL	1.1476 mL
	100 mM	0.0367 mL	0.1836 mL	0.3672 mL	0.9181 mL

Deoxyshikonin

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Deoxyshikonin

Anti-Infection Compound Library

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Quinones Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Deoxyshikonin

Alle HIF/HIF Prolyl-Hydroxylase Isoform-spezifische Produkte anzeigen

Alle PI3K Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Deoxyshikonin Related Classifications